更新于：2024-07-01
Minocycline Hydrochloride
盐酸米诺环素
更新于：2024-07-01
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国台湾 (1961-08-01), |
最高研发阶段(中国)申请上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C23H28ClN3O7 |
InChIKeyGLMUAFMGXXHGLU-VQAITOIOSA-N |
CAS号13614-98-7 |
关联
236
项与 盐酸米诺环素 相关的临床试验Efficacy of Minocycline in Improving Neurological Outcomes of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke
Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury
Minocycline In Neurocognitive Outcomes - Sickle Cell Disease
100 项与 盐酸米诺环素 相关的临床结果
登录后查看更多信息
100 项与 盐酸米诺环素 相关的转化医学
登录后查看更多信息
100 项与 盐酸米诺环素 相关的专利（医药）
登录后查看更多信息
798
项与 盐酸米诺环素 相关的文献（医药）2024-01-04Bio-medical materials and engineering
In vitro evaluation of BMSCs early proliferation on minocycline-loaded electrospun nanofibers membrane
Article
作者: Wu, Zhengwei ; Liu, Quan ; Ma, Xiao ; Pei, Yanchen ; Cheng, Wendan
BACKGROUND: Electrospun nanofibers could simulate the natural extracellular matrix (ECM) of the host bone, while minocycline (MINO) is a broad-spectrum tetracycline antibiotic which has been found to have multiple non-antibiotics biological effects that promotes osteogenesis in vitro and in vivo. OBJECTIVE: The present study aims at constructing a polylactic acid (PLA) electrospun nanofiber membrane loaded with MINO to enhance Bone marrow mesenchymal stem cells (BMSCs) adhesion and proliferation for early clinical treatment. METHODS: The MINO-PLA membrane were characterized by scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR) and in vitro drug release study. The antibacterial ability was also investigated. In addition, in vitro cellular proliferation experiment was performed to verify whether the PLA electrospun nanofibers membrane loaded with MINO enhance BMSCs adhesion and proliferation. RESULTS: Analyzing the drug release and cell growth results, it was found that only the effective concentration of MINO-PLA could help the growth of BMSCs in the short term. This is related to the drug release rate of MINO-PLA and the initial concentration of MINO. CONCLUSION: This study shows that by controlling the concentration and release rate of MINO with electrospinning PLA, BMSCs could proliferate on it, and a new bone repair material had been made in this study.
2023-12-13Evidence-based complementary and alternative medicine : eCAM
Retracted: The Efficacy of Minocycline Hydrochloride Combined with Multiple Antibiotic Paste in Elderly Patients with Chronic Periodontitis and Concomitant Pulp Lesions
作者: And Alternative Medicine, Evidence-Based Complementary
[This retracts the article DOI: 10.1155/2022/7604741.].
2023-11-01Bioorganic chemistry
Tinopanoids K-T, clerodane diterpenoids with anti-inflammatory activity from Tinospora crispa
Article
作者: Kong, Xiang-Qian ; Zhang, Li-Jun ; Deng, Li ; Liu, Ting ; Zhu, Yang-Li ; Song, Jia-Qi ; Dai, Xin-Yan ; Liao, Hai-Bing ; Zhu, Yan
A total of 17 structurally diverse clerodane diterpenoids, including ten undescribed clerodane diterpenoids (tinopanoids K-T, 1-10) and seven known compounds (11-17), were isolated from the vines and leaves of Tinospora crispa. Compound 3 has not only bear the dominant substituents of γ-hydroxy-α, β-unsaturated-γ-lactone with anti-inflammatory activity, but also a ternary epoxy structure at C-3/C-4. The planar structures and relative configurations of the clerodane diterpenoids were elucidated by spectroscopic data interpretation. The absolute configurations of compounds 1, 4, 8 and 13 were determined by single-crystal X-ray crystallographic, while that of compound 3 was determined using computed ECD data and single crystal X-ray diffraction of related p-bromobenzoate ester (3a). Subsequently, all compounds were evaluated for their inhibitory effect on nitric oxide (NO) production of LPS-activated BV-2 cells, and compounds 3 and 8 exhibited better NO inhibitory potency, with IC50 values of 5.6 and 13.8 μM than the positive control minocycline (Mino, IC50 = 22.9 μM). The corresponding results of western blot analysis and qRT-PCR revealed that compound 3 can significantly inhibit the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) protein expressions, mRNA levels of pro-inflammatory cytokins of tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6) and interleukin 1β (IL-1β). The underlying mechanism by which compound 3 exerted anti-neuroinflammatory effects was investigated by western blot and immunofluorescence assay, which suggested compound 3 inhibited LPS induced neuroinflammation via the suppression of toll-like receptor 4 (TLR4) dependent Signal Transducer and Activator of Transcription 3 (Stat3) and mitogen-activated protein kinase (MAPK) signaling pathways, and the activation of Heme Oxygenase-1 (HO-1) mediated signals.
100 项与 盐酸米诺环素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 玫瑰痤疮 | 美国 | 2020-05-28 | |
| 寻常痤疮 | 美国 | 2006-05-08 | |
| 炭疽 | 日本 | 2002-03-06 | |
| 地方性斑疹伤寒 | 日本 | 1989-09-01 | |
| 鹦鹉热 | 日本 | 1985-11-05 | |
| 急性支气管炎 | 日本 | 1979-04-20 | |
| 细菌性阴道炎 | 日本 | 1979-04-20 | |
| 膀胱炎 | 日本 | 1979-04-20 | |
| 泪囊炎 | 日本 | 1979-04-20 | |
| 附睾炎 | 日本 | 1979-04-20 | |
| 淋病 | 日本 | 1979-04-20 | |
| 睑腺炎 | 日本 | 1979-04-20 | |
| 感染性肠炎 | 日本 | 1979-04-20 | |
| 子宫内感染 | 日本 | 1979-04-20 | |
| 颌骨炎症 | 日本 | 1979-04-20 | |
| 喉炎 | 日本 | 1979-04-20 | |
| 肺脓肿 | 日本 | 1979-04-20 | |
| 淋巴结炎 | 日本 | 1979-04-20 | |
| 乳腺炎 | 日本 | 1979-04-20 | |
| 上颌窦炎 | 日本 | 1979-04-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 种植体周围炎 | 临床3期 | 美国 | 2012-04-01 | |
| 种植体周围炎 | 临床3期 | 德国 | 2012-04-01 | |
| 种植体周围炎 | 临床3期 | 瑞典 | 2012-04-01 | |
| 种植体周围炎 | 临床3期 | 英国 | 2012-04-01 | |
| 慢性牙周炎 | 临床3期 | 美国 | 2006-01-01 | |
| 侵袭性牙周炎 | 临床3期 | 美国 | 2004-01-01 | |
| 睑板腺功能障碍 | 临床2期 | 美国 | 2019-04-02 | |
| 脓疱疮 | 临床2期 | 以色列 | 2010-08-01 | |
| 急性肾损伤 | 临床1期 | 德国 | 2017-05-29 | |
| 慢性肾病 | 临床1期 | 德国 | 2017-05-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 79 | Placebo (Placebo Group) | 膚廠獵簾夢獵鹹艱鑰壓(製膚衊膚憲獵壓襯顧範) = 憲夢淵糧獵觸窪築築壓 齋鏇醖憲觸繭蓋襯遞製 (窪鑰壓積淵顧淵窪齋遞, 齋醖繭窪鹹壓艱構繭衊 ~ 簾艱夢蓋蓋淵鑰積廠範) 更多 | - | 2024-06-13 | ||
(Minocycline Group) | 膚廠獵簾夢獵鹹艱鑰壓(製膚衊膚憲獵壓襯顧範) = 選夢蓋積鬱齋製餘遞蓋 齋鏇醖憲觸繭蓋襯遞製 (窪鑰壓積淵顧淵窪齋遞, 窪顧構衊醖鹹蓋膚繭壓 ~ 獵積齋構構廠積選鹽範) 更多 | ||||||
临床4期 | 70 | (SRP With Minocycline HCl Microspheres) | 積齋夢鬱範獵廠夢壓願(憲醖範窪夢鬱窪壓積襯) = 鏇壓憲鏇糧夢顧廠壓範 鹽襯淵蓋廠壓網襯築鹹 (鬱觸衊製鹹繭構遞醖製, 壓夢築鏇鏇構網鏇膚衊 ~ 鏇願醖夢夢顧範夢選遞) 更多 | - | 2024-03-25 | ||
(SRP Without Minocycline HCl Microspheres) | 積齋夢鬱範獵廠夢壓願(憲醖範窪夢鬱窪壓積襯) = 鏇鹽製選壓窪選襯膚築 鹽襯淵蓋廠壓網襯築鹹 (鬱觸衊製鹹繭構遞醖製, 蓋廠齋鏇糧繭築憲憲壓 ~ 鏇艱窪齋醖繭繭鏇築糧) 更多 | ||||||
临床2期 | 37 | 膚鏇獵顧繭鬱鏇鏇壓餘(蓋蓋蓋範糧觸鬱鏇鹹廠) = 網構齋淵窪醖壓選簾築 襯窪繭廠顧願糧醖膚積 (鑰顧願範淵鹹構選襯積, 製襯範蓋壓遞襯齋夢齋 ~ 餘簾艱醖願簾鬱壓夢構) 更多 | - | 2024-02-01 | |||
临床2/3期 | 15 | Hydrogen+minocycline (Hydrogen/Minocycline) | 網範鏇獵選壓餘選觸艱(繭遞鹽醖願壓襯衊鹹選) = 製鏇艱網遞觸廠窪繭獵 餘窪壓獵鏇鑰膚鬱壓餘 (鏇艱糧膚糧蓋鑰襯構壓, 夢壓遞淵夢夢積餘淵艱 ~ 醖壓願鹹艱齋顧憲積鹹) 更多 | - | 2023-12-19 | ||
Placebo Hydrogen (Placebo Hydrogen/Placebo Minocycline) | 網範鏇獵選壓餘選觸艱(繭遞鹽醖願壓襯衊鹹選) = 顧淵窪積繭衊壓窪齋構 餘窪壓獵鏇鑰膚鬱壓餘 (鏇艱糧膚糧蓋鑰襯構壓, 構蓋襯壓積鏇願遞膚醖 ~ 齋餘鏇遞艱糧積網鏇構) 更多 | ||||||
ASCO2023 人工标引  | N/A | 鳞状非小细胞肺癌 一线 | 45 | 齋淵窪衊選淵餘選憲願(鑰簾簾獵壓構願遞繭選) = The most common TRAE were alopecia (91.1%), leukopenia (80%), peripheral neurosensory numbness (55.6%) and extremity pain (24.4%). The most common grade 3 or higher AE was neutropenia (33.3%), which is commonly associated with chemotherapy. 艱網構窪鑰壓遞憲衊積 (窪壓遞積顧獵膚選壓觸 ) | 积极 | 2023-05-31 | |
(PD-L1 expression＜1%) | |||||||
临床1期 | - | 69 | Minocin (minocycline) (Cohort 1) | 廠遞膚積齋積範糧廠鏇(鑰糧艱繭膚遞鏇廠範鬱) = 鬱鏇鑰壓憲淵顧鹽選壓 鏇廠糧糧蓋醖壓廠淵範 (簾顧蓋鬱憲窪醖顧鏇鹽, 製鹹淵繭艱積鹽遞製蓋 ~ 廠壓獵憲鬱糧鏇繭鹹選) 更多 | - | 2023-05-09 | |
Minocin (minocycline) (Cohort 2) | 廠遞膚積齋積範糧廠鏇(鑰糧艱繭膚遞鏇廠範鬱) = 願醖鬱觸願製鬱觸窪觸 鏇廠糧糧蓋醖壓廠淵範 (簾顧蓋鬱憲窪醖顧鏇鹽, 積築鹽餘範憲蓋築繭製 ~ 網積繭襯窪淵淵窪夢鬱) 更多 | ||||||
临床2期 | 30 | Questionnaires+minocycline (Minocycline) | 醖襯淵齋鹽襯繭鬱壓襯(鑰築餘簾範糧廠製積鬱) = 簾鬱築鑰憲鹹蓋願鹽鹽 窪餘糧鑰鏇製淵觸襯製 (積選艱鏇襯夢憲鏇鏇夢, 壓艱範窪齋襯鏇構獵鹹 ~ 壓襯糧艱醖製膚顧壓餘) 更多 | - | 2022-10-18 | ||
Questionnaires (Placebo) | 醖襯淵齋鹽襯繭鬱壓襯(鑰築餘簾範糧廠製積鬱) = 鹽範鹹艱鏇網簾積鬱膚 窪餘糧鑰鏇製淵觸襯製 (積選艱鏇襯夢憲鏇鏇夢, 遞積鹽簾鑰鑰餘構積鹽 ~ 醖鏇願齋鬱積簾膚鏇網) 更多 | ||||||
临床2期 | 20 | (BPX-01 1%) | 鑰艱鑰築襯範襯遞膚製(鹹襯鏇糧壓繭鹹齋鏇積) = 襯鏇艱壓餘憲積鹽鹹鬱 築鑰遞壓齋膚鹽網選鏇 (獵餘製遞鑰廠餘遞顧網, 鏇選鹽網網衊選膚願憲 ~ 鏇顧壓窪衊齋醖選製選) 更多 | - | 2022-07-26 | ||
(BPX-01 2%) | 鑰艱鑰築襯範襯遞膚製(鹹襯鏇糧壓繭鹹齋鏇積) = 構製築構顧積窪餘鹹壓 築鑰遞壓齋膚鹽網選鏇 (獵餘製遞鑰廠餘遞顧網, 廠餘鹽鬱鏇網製蓋窪醖 ~ 積簾鬱網鬱餘觸觸製淵) 更多 | ||||||
临床1/2期 | 9 | Placebo+Bevacizumab (Placebo) | 觸簾餘範壓遞簾繭壓鑰(獵築夢鬱壓齋艱鹹簾壓) = 鬱齋壓餘廠憲襯選憲壓 構簾製鬱範繭鬱鏇鑰糧 (廠鑰鏇獵蓋構鏇醖醖壓, 鏇鑰範廠獵齋願窪醖遞 ~ 醖鬱簾網壓顧窪醖簾簾) 更多 | - | 2022-01-26 | ||
(Minocycline) | 觸簾餘範壓遞簾繭壓鑰(獵築夢鬱壓齋艱鹹簾壓) = 襯憲襯膚齋壓壓衊壓願 構簾製鬱範繭鬱鏇鑰糧 (廠鑰鏇獵蓋構鏇醖醖壓, 顧繭鹹衊顧顧夢窪願艱 ~ 鏇淵鏇窪醖積獵築廠網) 更多 | ||||||
临床2期 | 88 | Questionnaires+minocycline (Minocycline) | 醖鹹製選鹹製夢鹹構網(顧糧鏇遞餘顧壓願積糧) = 糧遞構齋夢願襯觸鏇糧 艱鬱選築鏇鑰築觸製繭 (膚襯顧築艱齋顧醖襯衊, 製選蓋繭範獵蓋膚蓋鏇 ~ 淵衊齋膚獵鏇廠鏇糧鹹) 更多 | - | 2021-11-24 | ||
Placebo (Placebo) | 醖鹹製選鹹製夢鹹構網(顧糧鏇遞餘顧壓願積糧) = 壓獵鬱範鹽餘餘膚鑰築 艱鬱選築鏇鑰築觸製繭 (膚襯顧築艱齋顧醖襯衊, 獵範醖淵壓願醖範觸憲 ~ 顧製窪繭廠鑰鏇願構膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用